Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG StudyYuankai Shi, Chuan Gu, Lin Wu et al.|Journal of Thoracic Oncology|2022Cited by 79
Prevalence and cardiovascular risk factors of carotid plaque in rural-dwelling adults: a population-based study in Shandong, ChinaJie Zhang, Qinjian Sun, Yuanyuan Xiang et al.|Research Square|2021Cited by 0